Caribou Biosciences Is A Clinical Stage Biopharmaceutical Company Based In Berkeleycaliforniathe Company Focuses On Developing Genome Edited Allogeneic Cell Therapiesparticularly For Cancer Treatmentutilizing Proprietary Crispr Genome Editing Technologiesincluding Crispr Cas9 And Crispr Cas12Acaribou Aims To Enhance The Precision Of Its Therapies The Company Specializes In Next Generation Allogeneic Car T And Car Nk Cell Therapiesdesigned To Beoff The Shelffor Multiple Patientsits Pipeline Includes Several Candidatessuch As Cb 010 For B Cell Non Hodgkin Lymphomacb 011 For Relapsed Multiple Myelomacb 012 For Acute Myeloid Leukemiaand Cb 020An Ipsc Derived Car Nk Therapy For Solid Tumorscaribou Also Employs Its Patented Chrdna Technology For Complex Genome Editingimproving The Effectiveness Of Its Therapies Caribou Biosciences Collaborates With Notable Partnersincluding Abbvie Incand The Leukemia & Lymphoma Societyto Advance Its Researchthe Company Is Publicly Traded On Nasdaq Under The Ticker Symbol Crbu And Was Co Founded By Nobel Laureate Jennifer Doudnahighlighting Its Strong Foundation In Crispr Technology
